Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. It also focuses on developing novel drugs to solve pandemic-sized problems like the coronavirus disease. The company was founded by Uri A. Lopatin and Lee D. Arnold on February 27, 2020 and is headquartered in Carlsbad, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Pardes Biosciences Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Pardes Biosciences Inc market cap is $133.95M.
What is the 52-week high for Pardes Biosciences Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Pardes Biosciences Inc 52 week high is $3.41 as of September 18, 2025.
What is the 52-week low for Pardes Biosciences Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Pardes Biosciences Inc 52 week low is $0.75 as of September 18, 2025.
What is Pardes Biosciences Inc stock price today?
Pardes Biosciences Inc stock price today is $2.16.
What was Pardes Biosciences Inc stock price yesterday?
Pardes Biosciences Inc stock price yesterday was $2.16.
What is the PE ratio of Pardes Biosciences Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Pardes Biosciences Inc’s P/E ratio is -1.36.
What is the Price-to-Book ratio of Pardes Biosciences Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Pardes Biosciences Inc P/B ratio is 0.2893.
What is Pardes Biosciences Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Pardes Biosciences Inc's EBITDA is 0.53.
What is the 50-day moving average of Pardes Biosciences Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Pardes Biosciences Inc 50-day moving average is $2.05.